25 May 2023 
EMA/CHMP/221367/2023 
Committee for Medicinal Products for Human Use (CHMP)
Summary of opinion1 (post authorisation)
Sogroya
somapacitan
On 25 May 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Sogroya. 
The marketing authorisation holder for this medicinal product is Novo Nordisk A/S.
The CHMP recommended the addition of a new strength of 15 mg/1.5 mL solution for injection in pre-
filled pen.
The CHMP adopted an extension to an existing indication as follows:2 
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children 
aged 3 years and above and adolescents with growth failure due to growth hormone 
deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission.
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion
2 New text in bold
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union  
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.
